<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938574</url>
  </required_header>
  <id_info>
    <org_study_id>Atu027-I-01</org_study_id>
    <secondary_id>EudraCT-No: 2008-005588-32</secondary_id>
    <nct_id>NCT00938574</nct_id>
  </id_info>
  <brief_title>Study With Atu027 in Patients With Advanced Solid Cancer</brief_title>
  <official_title>A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silence Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silence Therapeutics GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an&#xD;
      siRNA formulation) given as single treatment followed by repeated treatment (repeated&#xD;
      treatment phase: 8 treatments within 4 weeks) as therapy in subjects with advanced solid&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of single and repeated intravenous infusion with Atu027 in subjects with advanced solid tumors</measure>
    <time_frame>treatment and follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of data concerning pharmacokinetics of Atu027 and its components</measure>
    <time_frame>treatment and follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of data concerning clinical safety and tolerability</measure>
    <time_frame>treatment and follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response as measured by RECIST criteria</measure>
    <time_frame>treatment and follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Drug Atu027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atu027</intervention_name>
    <arm_group_label>Drug Atu027</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically and/or cytologically proven advanced, recurrent or metastatic solid&#xD;
             malignancy for which standard curative or palliative measures do not exist, are no&#xD;
             longer effective, or are unlikely to be effective.&#xD;
&#xD;
          2. Age &gt;/= 18 years.&#xD;
&#xD;
          3. ECOG performance score of 0-2.&#xD;
&#xD;
          4. Life expectancy of at least 3 months.&#xD;
&#xD;
          5. Subjects must have recovered from the acute reversible effects of previous anti-cancer&#xD;
             therapies. At least 30 days since major surgery and at least 5 half-lives (t1/2) must&#xD;
             have elapsed since treatment with any investigational agent.&#xD;
&#xD;
          6. Adequate marrow, hepatic, renal, and heart function at the time of screening.&#xD;
&#xD;
          7. Weight &gt;/= 50kg.&#xD;
&#xD;
          8. Subjects must have at least one measurable lesion according to RECIST.&#xD;
&#xD;
          9. Women of childbearing potential must have a negative urine pregnancy test at baseline.&#xD;
&#xD;
         10. Women of childbearing potential and men must be willing to use highly effective&#xD;
             contraceptive methods during the course of the study and three months after.&#xD;
&#xD;
         11. Subjects must be willing and able (in the opinion of the investigator) to understand&#xD;
             the subject information and informed consent form and to comply with the study&#xD;
             protocol and procedures.&#xD;
&#xD;
         12. Subjects must be willing and able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of central nervous system (CNS) metastases.&#xD;
&#xD;
          2. Peripheral venous access insufficient to permit intravenous infusion or acquisition of&#xD;
             laboratory specimen.&#xD;
&#xD;
          3. Major surgery within 30 days prior to first study treatment.&#xD;
&#xD;
          4. Evidence that subject has only insufficiently recovered from the acute reversible&#xD;
             effects of previous anti-cancer therapies or surgery.&#xD;
&#xD;
          5. Abnormal hematologic parameters as defined:&#xD;
&#xD;
               -  Neutrophil count &lt; 1.500/mm3 (=1.5x10^9/l)&#xD;
&#xD;
               -  Platelet count &lt; 100.00/mm3 (=100x10^9/l)&#xD;
&#xD;
               -  White blood cells &lt; 3x10^9/l&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/l&#xD;
&#xD;
          6. Abnormal renal or hepatic function as defined:&#xD;
&#xD;
               -  ASAT (SGOT), ALAT (SGPT) &gt;/= 1.5xULN or &gt;/= 2.0xULN in case of liver metastases&#xD;
&#xD;
               -  Total bilirubin &gt;/= 1.5xULN&#xD;
&#xD;
               -  Creatinine clearance &lt; 50ml/min calculated by the Cockroft-Gault formula&#xD;
&#xD;
          7. Weight &lt; 50 kg.&#xD;
&#xD;
          8. Any concurrent disease, medical or social condition that could affect compliance with&#xD;
             the protocol or interpretation of results as judged by the investigator. In&#xD;
             particular, subjects with the following conditions are not allowed to enter the study:&#xD;
&#xD;
               -  Seizures&#xD;
&#xD;
               -  Poorly controlled Diabetes mellitus&#xD;
&#xD;
               -  Lipid metabolism disorder (cholesterol and triglycerides &gt;/= 1.5xULN), Refsum&#xD;
                  disease&#xD;
&#xD;
               -  Myocardial infarction within six (6) months prior to enrollment or having&#xD;
                  insufficient cardiac function defined as NYHA Grade 3 or 4, uncontrolled angina,&#xD;
                  cardiomyopathy, severe uncontrolled ventricular arrhythmias, left bundle branch&#xD;
                  block or electrocardiographic evidence of acute ischemic or active conduction&#xD;
                  system abnormalities (e.g. long QT interval, Torsade de Pointes)&#xD;
&#xD;
               -  Poorly controlled hypertension&#xD;
&#xD;
               -  Severe dyspnea or severe pulmonary dysfunction&#xD;
&#xD;
               -  Autoimmune and inflammatory disease&#xD;
&#xD;
               -  Active infection or known bacteremia&#xD;
&#xD;
               -  Known infection with HIV or chronic infection with hepatitis B or C virus&#xD;
&#xD;
               -  History of acute or chronic pancreatitis&#xD;
&#xD;
               -  Substance abuse&#xD;
&#xD;
          9. Prior gene transfer therapy.&#xD;
&#xD;
         10. Concurrent treatment with investigational or commercial agents or therapies&#xD;
             administered with the intention to treat the subject's malignancy.&#xD;
&#xD;
         11. Participation in any other clinical study or use of investigational device(s) during&#xD;
             participation in this study.&#xD;
&#xD;
         12. Known hypersensitivity to ingredients of the infusion solution.&#xD;
&#xD;
         13. Pregnant or nursing women or women of childbearing potential who are not willing to&#xD;
             use highly effective forms of contraception during participation in this study and at&#xD;
             least three months thereafter.&#xD;
&#xD;
         14. Male subjects with partners of child-bearing potential who are not willing to use&#xD;
             highly effective contraception during participation in this study and for at least&#xD;
             three months thereafter, unless surgically sterile.&#xD;
&#xD;
         15. Subject is a relative of, or staff directly reporting to the investigator or employee&#xD;
             of the sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Strumberg,, MD, Prof., Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Hematology &amp; Med. Oncology, Univ. of Bochum, Marienhospital Herne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Hematology &amp; Med. Oncology, Univ. of Bochum, Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

